Buradasınız

Anasayfa » Content

İleri Evre Yaşlı Küçük Hücreli Dışı Akciğer Kanseri Hastalarının Tedavisinde Sisplatin ve Etoposid

Cisplatin and etoposide in the treatment of elderly patients with advanced non-small cell lung cancer

Journal Name:

  • Uludağ Üniversitesi Tıp Fakültesi Dergisi

Publication Year:

  • 2003

Key Words:

Keywords (Original Language):

Author NameUniversity of Author
Abstract (2. Language): 
The aims of the present study were to test activity and tolerability of cisplatin and etoposide in advanced non-small cell lung cancer (NSCLC) patients aged 70 years or higher. Twenty-four patients were enrolled. Cisplatin was given at a dose of 60 mg/m 2 on day 1 and etoposide at a dose of 120 mg/m 2 on days 1-3. Total 116 courses were administered. Twelve patients (50%) completed all six cycles of treatment. Three patients (12.5%) obtained a partial response, as well as 12 (50%) stable disease and 9 (37.5%) progressive disease. The median survival was 48.5 ± 6.06 weeks, and the 1 year survival rate was 38%. Grade 3-4 neutropenia occurred in 16.6% of patients, grade 4 thrombocytopenia in %4.1, and grade 1-2 neuropathy in 25%. One patient discontinued treatment due to grade 3 nephrotoxicity. In conclusion, cisplatin and etoposide regimen is active and relatively well-tolerated in the treatment of elderly NSCLC patients. New, active and well-tolerated combination regimens could improve present results.
Bookmark/Search this post with
Abstract (Original Language): 
Bu çalışmanın amaçları 70 yaş ve üzeri ileri evre küçük hücreli dışı akciğer kanseri (KHDAK) hastalarında sisplatin ve etoposid tedavisinin aktivitesini ve tolerabilitesini araştırmaktı. Yirmi dört hasta çalışmaya alındı. Sisplatin 60 mg/m2 dozunda 1. günde ve etoposid 120 mg/m2 dozunda 1-3. günlerde verildi. Toplam 116 siklus uygulandı. On iki (%50) hasta altı siklus tedaviyi tamamladı. Üç hastada (%12.5) kısmi yanıt elde edilirken, 12 hastada (%50) stabil hastalık ve 9 hastada (%37.5) progresyon mevcuttu. Ortalama sağ kalım 48.5 ± 6.06 hafta ve 1 yıllık sağ kalım oranı %38’di. Grade 3-4 nötropeni hastaların %16.6’ında, grade 4 trombositopeni %4.1’nde ve grade 1-2 nöropati %25’inde görüldü. Bir hastada grade 3 nefrotoksisite nedeniyle tedavi sonlandırıldı. Sonuç olarak sisplatin ve etoposid yaşlı KHDAK hastalarının tedavisinde aktiftir ve nisbeten iyi tolere edilmektedir. Yeni, aktif ve iyi tolere edilen rejimler mevcut sonuçları iyileştirebilir.
FULL TEXT (PDF): 
PDF icon arastirmax-ileri-evre-yasli-kucuk-hucreli-disi-akciger-kanseri-hastalarinin-tedavisinde-sisplatin-etoposid.pdf
  • 1
25-28
  • Turkish

REFERENCES

References: 

1. Silverberg E. Cancer statistics. CA J 1988; 38:5-22.
2. Non-small Cell Lung Cancer Collaborative Group.
Chemotherapy in non-small cell lung cancer: a meta-analysis
using updated data on individual patients from 52
randomized clinical trials. BMJ 1995; 311:899-909.
3. Gridelli C, Perrone F, Monfardini S. Lung cancer in elderly.
Eur J Cancer 1997; 33:2313-4.
4. Miller AB, Hoogstraten B, Staquet MMiller AB, Hoogstraten
B, Staquet M, Winkler A. Reporting results of cancer
treatment. Cancer 1981; 47:207-14.
5. Kaplan EL, Meier P. Non-parametric estimation from
incomplete observation. J Am Stat Assoc 1958;53:457-81.
6. Kubota K, Furuse K, Kawahara M, et al. Cisplatin-based
combination chemotherapy for elderly patients with lung
cancer. Cancer Chemother Pharmacol 1997; 40:469-74.
7. Souquet PJ, Bombaron P, Brunel-Crova J, et al. Treatment of
advanced and disseminated non-small cell lung cancer
(NSCLC) in elderly patients: results of MIC regimen. Lung
Cancer 1997; 18 (Suppl 1):24.
8. Gridelli C, Perrone F, Gallo C, et al. Vinorelbine is well
tolerated and active in the treatment of elderly patients with
advanced non-small cell lung cancer. A two stage phase II
study. Eur J Cancer 1997; 33:392-7.
9. The Elderly Lung Cancer Vinorelbine Italian Study Group.
Effect of vinorelbine on quality of life and survival of elderly
patients with advanced nonsmall cell lung cancer. J Natl
Cancer Inst 1999; 91:66-72.
10. Furuse K. Gemcitabine in the treatment of non-small cell
lung cancer for elderly patients. Gan To Kagaku Ryoho
1999; 26:890-7.
11. Ricci S, Antonuzzo A, Galli L, et al. Gemcitabine
monotherapy in elderly patients with advanced non-small
cell lung cancer. A multicenter phase II study. Lung Cancer
2000; 27:75-80.
12. Pasquini E, Tassinari D, Nicolini M. Gemcitabine in
advanced non small cell lung cancer (NSCLC): a valid
option in geriatric patients. Lung Cancer 1999; 24:202.
13. Felui J, Gomez LL, Espinosa E, et al. Gemcitabine plus
vinorelbine in non-small cell lung carcinoma patients age 70
years or older or patients who cannot receive cisplatin.
Cancer 1999; 86:1463-9.
14. Beretta GD, Michetti G, Belometti MO, et al. Gemcitabine
plus vinorelbine in elderly or unfit patients with non-small
cell lung cancer. Br J Cancer 2000;83:573-6.
15. Frasci G, Lorusso V, Panza N, et al. Gemcitabine plus
vinorelbine versus vinorelbine alone in elderly patients with
advanced non-small-cell lung cancer. J Clin Oncol 2000;
18:2529-36.
16. Gridelli C, Perone F, Cigolari S, et al. The MILES
(Multicenter Italian Lung Cancer in the Elderly Study) phase
III trial: Gemcitabine + vinorelbine vs vinorelbin and vs
gemcitabine in elderly advanced NSCLC patients. Proc Am
Soc Clin Oncol 2001; 20:308a.
17. Hainsworth JD, Burris HA, Litchy S, et al. Weekly docetaxel
in the treatment of elderly patients with advanced non-small
cell lung carcinoma. Cancer 2000; 89:328-33.

Thank you for copying data from http://www.arastirmax.com